Gilead wins speedy FDA review for latest hep C combo
Gilead Sciences already reaps billions from its hep C meds Sovaldi and Harvoni, but the company isn't content to sit back with the status quo. It's prepping a new hep C combo for FDA approval and recently got a boost after the agency granted the med a speedy review. The FDA gave its priority review designation to Gilead's new combo pill, which includes Sovaldi and investigational compound velpatasvir and treats genotypes 1-6 of the virus.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063